The FDA recently announced that it approved a record-breaking number of generic drugs in October 2018.
The FDA recently announced that it approved a record-breaking number of generic drugs in October 2018.
In total, the FDA put out 128 approval actions last month. Of these, 110 generic drugs were approved, and 18 other generic drugs were tentatively approved. This number includes 23 first generics for products that previously lacked competition, and 17 complex generics (FDA’s data also include 1 biosimilar adalimumab product).
“The FDA plays an important role in approving high-quality medicines and promoting more generic drug competition. Over the past 2 consecutive years, the agency approved record numbers of generic drugs,” said FDA Commissioner Scott Gottlieb, MD. “Now we’re beginning the new fiscal year by breaking another record, this time with the highest number of approved or tentatively approved generics ever in a month.”
Gottlieb explained that, through the agency’s efforts, generic drugs that entered the market from January 2017 through July 2018 were able to save consumers $26 billion. Additionally, these efforts are also reducing the number of review cycles for generic drug applications, making the process more efficient so the agency is able to dedicate its resources to getting the “quality generic medications” to patients sooner.
Furthermore, last month, the FDA also issued a series of guidance documents aimed at advancing the development of generic transdermal and topical delivery systems. These guidance documents allow for increased transparency from the FDA to applicants seeking approval of generic versions of complex products by explaining how to more efficiently prepare better and more complete applications.
“We’ll continue our efforts to increase competition and help lower costs for patients with our Drug Competition Action Plan and will do so by continuing to advance policies that increase the efficiency of our generic drug program and working to approve high quality generic medicines that meet our standards,” said Gottlieb.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.